文献
(601～700)601. Andersson C, Olesen JB, Hansen PR, et al. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart
failure: a retrospective nationwide cohort study. Diabetologia 2010; 53: 2546-2553. PMID: 20838985
602. Aguilar D, Chan W, Bozkurt B, et al. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail
2011; 4: 53-58. PMID: 20952583
603. Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart
failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail 2013; 6: 395-402. PMID: 23508758
604. Crowley MJ, Diamantidis CJ, McDuffie JR, et al. Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease,
Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. Ann Intern Med 2017; 166: 191-200. PMID: 28055049
605. Authors/Task Force Members, Rydén L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular
diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the
European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD).
Eur Heart J 2013; 34: 3035-3087. PMID: 23996285
606. Scirica BM, Bhatt DL, Braunwald E, et al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular
outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326. PMID: 23992601
607. White WB, Cannon CP, Heller SR, et al. EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2
diabetes. N Engl J Med 2013; 369: 1327-1335. PMID: 23992602
608. Green JB, Bethel MA, Armstrong PW, et al. TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
N Engl J Med 2015; 373: 232-242. PMID: 26052984
609. Pfeffer MA, Claggett B, Diaz R, et al. ELIXA Investigators. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
N Engl J Med 2015; 373: 2247-2257. PMID: 26630143
610. Marso SP, Daniels GH, Brown-Frandsen K, et al. LEADER Steering Committee. Liraglutide and Cardiovascular Outcomes in Type 2
Diabetes. N Engl J Med 2016; 375: 311-322. PMID: 27295427
611. Marso SP, Bain SC, Consoli A, et al. SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2
Diabetes. N Engl J Med 2016; 375: 1834-1844. PMID: 27633186
612. Scirica BM, Braunwald E, Raz I, et al. SAVOR-TIMI 53 Steering Committee and Investigators. Heart failure, saxagliptin, and diabetes
mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2014; 130: 1579-1588. PMID: 25189213
613. Margulies KB, Hernandez AF, Redfield MM, et al. NHLBI Heart Failure Clinical Research Network. Effects of Liraglutide on Clinical
Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA 2016; 316:
500-508. PMID: 27483064
614. Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus:
Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation 2016; 134: 752-772. PMID: 27470878
615. Tanaka A, Node K. Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology. J Cardiol 2017; 69: 501-507. PMID:
28043708
616. Damman K, Valente MA, Voors AA, et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: an
updated meta-analysis. Eur Heart J 2014; 35: 455-469. PMID: 24164864
617. Krum H, Roecker EB, Mohacsi P, et al. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effects
of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA 2003; 289: 712-718.
PMID: 12585949
618. Wali RK, Iyengar M, Beck GJ, et al. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-
analysis of randomized trials. Circ Heart Fail 2011; 4: 18-26. PMID: 21036889
619. Castagno D, Jhund PS, McMurray JJ, et al. Improved survival with bisoprolol in patients with heart failure and renal impairment: an
analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. Eur J Heart Fail 2010; 12: 607-616. PMID: 20354032
620. Tang CH, Wang CC, Chen TH, et al. Prognostic Benefits of Carvedilol,Bisoprolol, and Metoprolol Controlled Release/Extended Release
in Hemodialysis Patients with Heart Failure: A 10-Year Cohort. J Am Heart Assoc 2016; 5: e002584. PMID: 26738790
621. Edner M, Benson L, Dahlström U, et al. Association between renin- angiotensin system antagonist use and mortality in heart failure
with severe renal insufficiency: a prospective propensity scorematched cohort study. Eur Heart J 2015; 36: 2318-2326. PMID:
26069212
622. 日本腎臓学会．CKD診療ガイド2012．東京医学社 2012.
623. Vardeny O, Wu DH, Desai A, et al. RALES Investigators. Influence of baseline and worsening renal function on efficacy of spironolactone
in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol 2012; 60:
2082-2089. PMID: 23083787
624. Eschalier R, McMurray JJ, Swedberg K, et al. EMPHASIS-HF Investigators. Safety and efficacy of eplerenone in patients at high risk for
hyperkalemia and/or worsening renal function: analyses of the EMPHASIS- HF study subgroups (Eplerenone in Mild Patients
Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol 2013; 62: 1585-1593. PMID: 23810881
625. Cosín J, Díez J. TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002; 4: 507-
513. PMID: 12167392
626. Shlipak MG, Smith GL, Rathore SS, et al. Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin
intervention group trial. J Am Soc Nephrol 2004; 15: 2195-2203. PMID: 15284305
627. Gheorghiade M, Böhm M, Greene SJ, et al. ASTRONAUT Investigators and Coordinators. Effect of aliskiren on postdischarge mortality
and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 2013; 309: 1125-
1135. PMID: 23478743
628. Sezai A, Hata M, Niino T, et al. Influence of continuous infusion of low-dose human atrial natriuretic peptide on renal function during
cardiac surgery: a randomized controlled study. J Am Coll Cardiol 2009; 54: 1058-1064. PMID: 19744614
629. Morikawa S, Sone T, Tsuboi H, et al. Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic
peptide. J Am Coll Cardiol 2009; 53: 1040-1046. PMID: 19298916
630. Nigwekar SU, Navaneethan SD, Parikh CR, et al. Atrial natriuretic peptide for management of acute kidney injury: a systematic review
and meta-analysis. Clin J Am Soc Nephrol 2009; 4: 261-272. PMID: 19073785
631. Vaduganathan M, Gheorghiade M, Pang PS, et al. EVEREST investigators. Efficacy of oral tolvaptan in acute heart failure patients with
hypotension and renal impairment. J Cardiovasc Med (Hagerstown) 2012; 13: 415-422. PMID: 22673023
632. Matsue Y, Suzuki M, Torii S, et al. Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction. J
Card Fail 2016; 22: 423-432. PMID: 26915749
633. Bock JS, Gottlieb SS. Cardiorenal syndrome: new perspectives. Circulation 2010; 121: 2592-2600. PMID: 20547939
634. 日本痛風・核酸代謝学会ガイドライン改訂委員会．高尿酸血症・痛風の治療ガイドライン第2版．メディカルレビュー社 2010.
635. Givertz MM, Anstrom KJ, Redfield MM, et al. NHLBI Heart Failure Clinical Research Network. Effects of Xanthine Oxidase Inhibition in
Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study.
Circulation 2015; 131: 1763-1771. PMID: 25986447
636. Global Initiative for Asthma. 2016 GINA Report, Global Strategy for Asthma Management and Prevention.
637. Global Initiative for Chronic Obstructive Lung Disease. GOLD 2017: Global Strategy for the Diagnosis, Management and Prevention of
638. Bhatt SP, Dransfield MT. Chronic obstructive pulmonary disease and cardiovascular disease. Transl Res 2013; 162: 237-251. PMID:
23727296
639. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary
disease and chronic heart failure. J Am Coll Cardiol 2007; 49: 171-180. PMID: 17222727
640. Yoshihisa A, Takiguchi M, Shimizu T, et al. Cardiovascular function and prognosis of patients with heart failure coexistent with chronic
obstructive pulmonary disease. J Cardiol 2014; 64: 256-264. PMID: 24674751
641. Chen W, Thomas J, Sadatsafavi M, et al. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a
systematic review and meta-analysis. Lancet Respir Med 2015; 3: 631-639. PMID: 26208998
642. Hawkins NM, Virani S, Ceconi C. Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health
services. Eur Heart J 2013; 34: 2795-2803. PMID: 23832490
643. Rutten FH, Cramer MJ, Grobbee DE, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary
disease. Eur Heart J 2005; 26: 1887-1894. PMID: 15860516
644. Forth R, Montgomery H. ACE in COPD: a therapeutic target? Thorax 2003; 58: 556-558. PMID: 12832663
645. Lipworth B, Wedzicha J, Devereux G, et al. Beta-blockers in COPD: time for reappraisal. Eur Respir J 2016; 48: 880-888. PMID:
27390282
646. Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta- blockers in patients with chronic heart failure and chronic
obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol 2010; 55: 1780-1787. PMID: 20413026
647. Morales DR, Jackson C, Lipworth BJ, et al. Adverse respiratory effect of acute β-blocker exposure in asthma: a systematic review and
meta-analysis of randomized controlled trials. Chest 2014; 145: 779- 786. PMID: 24202435
648. Morales DR, Lipworth BJ, Donnan PT, et al. Respiratory effect of beta- blockers in people with asthma and cardiovascular disease:
population- based nested case control study. BMC Med 2017; 15: 18. PMID: 28126029
649. Kajimoto K, Sato N, Takano T. investigators of the Acute Decompensated Heart Failure Syndromes (ATTEND) registry. Association
between anemia, clinical features and outcome in patients hospitalized for acute heart failure syndromes. Eur Heart J Acute Cardiovasc
Care 2015; 4: 568-576. PMID: 25315117
650. Hamaguchi S, Tsuchihashi-Makaya M, Kinugawa S, et al. JCARECARD Investigators. Anemia is an independent predictor of longterm
adverse outcomes in patients hospitalized with heart failure in Japan. A report from the Japanese Cardiac Registry of Heart Failure
in Cardiology (JCARE-CARD). Circ J 2009; 73: 1901-1908. PMID: 19652398
651. Yamauchi T, Sakata Y, Takada T, et al. CHART-2 investigators. Prognostic Impact of Anemia in Patients With Chronic Heart Failure-
With Special Reference to Clinical Background: Report From the CHART-2 Study. Circ J 2015; 79: 1984-1993. PMID: 26050711
652. Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart
J 2010; 31: 1872-1880. PMID: 20570952
653. Cohen-Solal A, Damy T, Terbah M, et al. High prevalence of iron deficiency in patients with acute decompensated heart failure. Eur J
Heart Fail 2014; 16: 984-991. PMID: 25065368
654. Anker SD, Comin Colet J, Filippatos G, et al. FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron
deficiency. N Engl J Med 2009; 361: 2436-2448. PMID: 19920054
655. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. CONFIRM- HF Investigators. Beneficial effects of long-term intravenous
iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015; 36: 657-668.
PMID: 25176939
656. Lewis GD, Malhotra R, Hernandez AF, et al. NHLBI Heart Failure Clinical Research Network. Effect of Oral Iron Repletion on Exercise
Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical
Trial. JAMA 2017; 317: 1958-1966. PMID: 28510680
657. McIntyre L, Tinmouth AT, Fergusson DA. Blood component transfusion in critically ill patients. Curr Opin Crit Care 2013; 19: 326-333.
PMID: 23817027
658. Swedberg K, Young JB, Anand IS, et al. RED-HF Committees. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl
J Med 2013; 368: 1210-1219. PMID: 23473338
659. Oldenburg O, Lamp B, Faber L, et al. Sleep-disordered breathing in patients with symptomatic heart failure: a contemporary study of
prevalence in and characteristics of 700 patients. Eur J Heart Fail 2007; 9: 251-257. PMID: 17027333
660. Yumino D, Wang H, Floras JS, et al. Prevalence and physiological predictors of sleep apnea in patients with heart failure and systolic
dysfunction. J Card Fail 2009; 15: 279-285. PMID: 19398074
661. Javaheri S. Sleep disorders in systolic heart failure: a prospective study of 100 male patients. The final report. Int J Cardiol 2006; 106:
21-28. PMID: 16321661
662. Chan J, Sanderson J, Chan W, et al. Prevalence of sleep-disordered breathing in diastolic heart failure. Chest 1997; 111: 1488-1493.
PMID: 9187161
663. Bitter T, Faber L, Hering D, et al. Sleep-disordered breathing in heart failure with normal left ventricular ejection fraction. Eur J Heart Fail
2009; 11: 602-608. PMID: 19468022
664. 日本循環器学会．循環器病の診断と治療に関するガイドライン． 循環器領域における睡眠呼吸障害の診断・治療に関するガイドライン．Circ J
2010; 74 Suppl II: 963-1084.
665. Kasai T, Floras JS, Bradley TD. Sleep apnea and cardiovascular disease: a bidirectional relationship. Circulation 2012; 126: 1495-1510.
PMID: 22988046
666. Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or
without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365: 1046-1053. PMID: 15781100
667. Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart
failure: the sleep heart health study. Circulation 2010; 122: 352-360. PMID: 20625114
668. Kasai T. Sleep apnea and heart failure. J Cardiol 2012; 60: 78-85. PMID: 22824295
669. Yumino D, Redolfi S, Ruttanaumpawan P, et al. Nocturnal rostral fluid shift: a unifying concept for the pathogenesis of obstructive and
central sleep apnea in men with heart failure. Circulation 2010; 121: 1598-1605. PMID: 20351237
670. Roebuck T, Solin P, Kaye DM, et al. Increased long-term mortality in heart failure due to sleep apnoea is not yet proven. Eur Respir J
2004; 23: 735-740. PMID: 15176689
671. Wang H, Parker JD, Newton GE, et al. Influence of obstructive sleep apnea on mortality in patients with heart failure. J Am Coll Cardiol
2007; 49: 1625-1631. PMID: 17433953
672. Javaheri S, Shukla R, Zeigler H, et al. Central sleep apnea, right ventricular dysfunction, and low diastolic blood pressure are predictors
of mortality in systolic heart failure. J Am Coll Cardiol 2007; 49: 2028-2034. PMID: 17512359
673. Arzt M, Young T, Finn L, et al. Sleepiness and sleep in patients with both systolic heart failure and obstructive sleep apnea. Arch Intern
Med 2006; 166: 1716-1722. PMID: 16983049
674. Bucca CB, Brussino L, Battisti A, et al. Diuretics in obstructive sleep apnea with diastolic heart failure. Chest 2007; 132: 440-446. PMID:
17699130
675. Tamura A, Kawano Y, Kadota J. Carvedilol reduces the severity of central sleep apnea in chronic heart failure. Circ J 2009; 73: 295-298.
PMID: 19122306
676. Lamba J, Simpson CS, Redfearn DP, et al. Cardiac resynchronization therapy for the treatment of sleep apnoea: a meta-analysis.
Europace 2011; 13: 1174-1179. PMID: 21561903
677. Kaneko Y, Floras JS, Usui K, et al. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and
obstructive sleep apnea. N Engl J Med 2003; 348: 1233-1241. PMID: 12660387
678. Sun H, Shi J, Li M, et al. Impact of continuous positive airway pressure treatment on left ventricular ejection fraction in patients with
obstructive sleep apnea: a meta-analysis of randomized controlled trials. PLoS One 2013; 8: e62298. PMID: 23650511
679. Kasai T, Narui K, Dohi T, et al. Prognosis of patients with heart failure and obstructive sleep apnea treated with continuous positive airway
pressure. Chest 2008; 133: 690-696. PMID: 18198253
680. Damy T, Margarit L, Noroc A, et al. Prognostic impact of sleep-disor dered breathing and its treatment with nocturnal ventilation for chronic
heart failure. Eur J Heart Fail 2012; 14: 1009-1019. PMID: 22730336
681. Barbé F, Durán-Cantolla J, Sánchez-de-la-Torre M, et al. Spanish Sleep And Breathing Network. Effect of continuous positive airway
pressure on the incidence of hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized
controlled trial. JAMA 2012; 307: 2161-2168. PMID: 22618923
682. McEvoy RD, Antic NA, Heeley E, et al. SAVE Investigators and Coordinators. CPAP for Prevention of Cardiovascular Events in Obstructive
Sleep Apnea. N Engl J Med 2016; 375: 919-931. PMID: 27571048
683. Lyons OD, Floras JS, Logan AG, et al. ADVENT-HF Investigators. Design of the effect of adaptive servo-ventilation on survival and
cardiovascular hospital admissions in patients with heart failure and sleep apnoea: the ADVENT-HF trial. Eur J Heart Fail 2017; 19: 579-
587. PMID: 28371141
684. Bradley TD, Logan AG, Kimoff RJ, et al. CANPAP Investigators. Continuous positive airway pressure for central sleep apnea and heart
failure. N Engl J Med 2005; 353: 2025-2033. PMID: 16282177
685. Arzt M, Floras JS, Logan AG, et al. CANPAP Investigators. Suppression of central sleep apnea by continuous positive airway pressure
and transplant-free survival in heart failure: a post hoc analysis of the Canadian Continuous Positive Airway Pressure for Patients with
Central Sleep Apnea and Heart Failure Trial (CANPAP). Circulation2007; 115: 3173-3180. PMID: 17562959
686. Kasai T, Kasagi S, Maeno K, et al. Adaptive servo-ventilation in cardiac function and neurohormonal status in patients with heart failure
and central sleep apnea nonresponsive to continuous positive airway pressure. JACC Heart Fail 2013; 1: 58-63. PMID: 24621799
687. Kasai T, Usui Y, Yoshioka T, et al. JASV Investigators. Effect of flow-triggered adaptive servo-ventilation compared with continuous
positive airway pressure in patients with chronic heart failure with coexisting obstructive sleep apnea and Cheyne-Stokes respiration.
Circ Heart Fail 2010; 3: 140-148. PMID: 19933407
688. Sharma BK, Bakker JP, McSharry DG, et al. Adaptive servoventilation for treatment of sleep-disordered breathing in heart failure: a
systematic review and meta-analysis. Chest 2012; 142: 1211-1221. PMID: 22722232
689. Aurora RN, Chowdhuri S, Ramar K, et al. The treatment of central sleep apnea syndromes in adults: practice parameters with an
evidence- based literature review and meta-analyses. Sleep 2012; 35: 17- 40. PMID: 22215916
690. Yoshihisa A, Shimizu T, Owada T, et al. Adaptive servo ventilation improves cardiac dysfunction and prognosis in chronic heart failure
patients with Cheyne-Stokes respiration. Int Heart J 2011; 52: 218- 223. PMID: 21828947
691. Javaheri S. Pembrey’s dream: the time has come for a long-term trial of nocturnal supplemental nasal oxygen to treat central sleep apnea
in congestive heart failure. Chest 2003; 123: 322-325. PMID: 12576341
692. Shigemitsu M, Nishio K, Kusuyama T, et al. Nocturnal oxygen therapy prevents progress of congestive heart failure with central sleep
apnea. Int J Cardiol 2007; 115: 354-360. PMID: 16806535
693. Toyama T, Seki R, Kasama S, et al. Effectiveness of nocturnal home oxygen therapy to improve exercise capacity, cardiac function and
cardiac sympathetic nerve activity in patients with chronic heart failure and central sleep apnea. Circ J 2009; 73: 299-304. PMID:19122308
694. Sasayama S, Izumi T, Seino Y, et al. CHF-HOT Study Group. Effects of nocturnal oxygen therapy on outcome measures in patients with
chronic heart failure and cheyne-stokes respiration. Circ J 2006; 70: 1-7. PMID: 16377916
695. Sasayama S, Izumi T, Matsuzaki M, et al. CHF-HOT Study Group. Improvement of quality of life with nocturnal oxygen therapy in heart
failure patients with central sleep apnea. Circ J 2009; 73: 1255-1262. PMID: 19448327
696. Murase K, Ono K, Yoneda T, et al. Adaptive servoventilation versus oxygen therapy for sleep disordered breathing in patients with heart
failure: a randomised trial. Open Heart 2016; 3: e000366. PMID: 27099761
697. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure.
Am Heart J 2007; 154: 260-266. PMID: 17643574
698. Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol
1967; 20: 457-464. PMID: 6059183
699. Miller WL, Wright RS, Grill JP, et al. Improved survival after acute myocardial infarction in patients with advanced Killip class. Clin
Cardiol 2000; 23: 751-758. PMID: 11061053
700. Halkin A, Singh M, Nikolsky E, et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial
infarction: the CADILLAC risk score. J Am Coll Cardiol 2005; 45: 1397-1405. PMID: 15862409
急性･慢性心不全診療ガイドライン（2017年改訂版）
Guidelines for Diagnosis and Treatment of Acute and Chronic Heart Failure
（JCS 2017/JHFS 2017）